Back

Natural course and effect of tafamidis treatment in real-life octogenarians with wild-type transthyretin cardiac amyloidosis: an international multi-centre analysis.

30 August 2024 (08:00 - 17:30)
Organised by: Logo
Congress Presentation Part of: Cardiac amyloidosis: diagnosis and outcomes Infiltrative Myocardial Disease ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Doctor Philippe Debonnaire

AZ Sint Jan, Brugge (Belgium)

7 More presentations in this session

Presentation thumbnail
Artificial intelligence to assist the echocardiographic identification of transthyretin cardiac amyloidosis
Doctor V. Algalarrondo (Paris, FR)
Abstract Slides
Presentation thumbnail
Increased index of microcirculatory resistance, capillary rarefaction, elevated troponin levels, and their association with transthyretin amyloidosis cardiomyopathy
Mr Y. Suiko (Miyazaki, JP)
Abstract Slides
Presentation thumbnail
Association of cardiac amyloidosis with cardiovascular outcomes after aortic valve replacement in patients with severe aortic stenosis: a systematic review and meta-analysis
Doctor T. Figueira (Stony Brook, US)
Abstract Slides
Presentation thumbnail
RV-PA uncoupling is a strong predictor of 3-year all-cause mortality in transthyretin amyloid cardiomyopathy.
Doctor S. Schwarting (Munich, DE)
Abstract Slides Video
Presentation thumbnail
Increase in serum TTR levels observed with acoramidis treatment in patients with transthyretin amyloid cardiomyopathy (ATTR-CM): insights from ATTRibute-CM and its open-label extension
Doctor M. Maurer (New York, US)
Abstract Slides

Access the full session

Session thumbnail
Cardiac amyloidosis: diagnosis and outcomes

The Event

Event poster

ESC Congress 2024

30 August - 2 September 2024
You may be interested in
thumbnail
Congress Presentation
Decoding the decades: Tafamidis efficacy across different age groups in ATTR-CM patients
thumbnail
Congress Presentation
Impact of Tafamidis on clinical outcomes in real-world patients with ATTR-CM
thumbnail
Congress Presentation
Tafamidis treatment for transthyretin amyloid cardiomyopathy: results from an open-label, early-access, long-term study extension in an all-comers population

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources